Question 1
Difficulty: medium
Can you walk me through how you would design a bioinformatics pipeline for processing whole-genome sequencing data from raw FASTQ files to variant calls?
Sample answer
I’d start by clarifying the use case: germline or somatic, short-read or long-read, expected throughput, and downstream consumers. From there I’d design the pipeline around reproducibility and traceability. The core steps would include FASTQ quality control, adapter trimming if needed, alignment to the correct reference genome, duplicate marking, base quality recalibration when appropriate, and variant calling with a tool matched to the study type. I’d also build in QC checkpoints at each stage, such as mapping rate, duplicate rate, coverage distribution, and contamination checks. For implementation, I’d use a workflow manager like Nextflow or Snakemake, containerize tools for version stability, and separate compute-intensive steps from reporting. I’d also think early about metadata handling, sample sheet validation, and error recovery so runs can resume cleanly. Finally, I’d make sure the outputs are easy for analysts to consume, with standardized VCFs, logs, and a summary report that highlights any sample-level issues.
Question 2
Difficulty: medium
How do you balance biological accuracy with software engineering best practices when building analysis pipelines?
Sample answer
I think the key is to treat the pipeline as both a scientific instrument and a software product. On the biology side, I make sure the pipeline reflects the assumptions of the assay and the experiment, because a technically elegant pipeline is useless if it gives the wrong answer for the dataset. On the engineering side, I focus on modular design, version control, automated testing, and clear interfaces between steps. For example, if I’m building a variant-calling workflow, I’ll keep alignment, QC, and calling as separate modules so each can be validated independently. I also like to create test datasets with known expected outputs so I can catch regressions when a tool version changes. When there’s a tradeoff, I usually push for a configurable approach rather than hardcoding choices. That gives scientists flexibility while preserving consistency and auditability. In my experience, the best pipelines are the ones people trust because they are both scientifically sound and operationally stable.
Question 3
Difficulty: hard
Describe a time you had to troubleshoot a bioinformatics result that looked biologically suspicious. How did you approach it?
Sample answer
I’d start by assuming the result might be real, but I’d try to disprove it systematically. In one case, a variant set showed an unusually high number of calls in a region that didn’t fit the biology of the sample type. I first checked basic pipeline outputs: read depth, mapping quality, duplicate rate, and whether the region was known to be repetitive or poorly mappable. Then I reviewed the alignments in a genome browser to see whether the signal came from misaligned reads, strand bias, or a local reference issue. I also compared the sample against controls and looked for batch effects across the run. The issue turned out to be a combination of a low-complexity region and a parameter setting that was too permissive for that assay. I documented the finding, adjusted the filtering strategy, and added a QC rule so similar cases would be flagged earlier. What I learned is that good troubleshooting is part technical analysis and part disciplined elimination of assumptions.
Question 4
Difficulty: medium
What experience do you have with workflow managers such as Nextflow, Snakemake, or WDL, and why would you choose one over another?
Sample answer
I’ve worked with workflow managers because they solve real problems around reproducibility, scaling, and maintainability. My default choice depends on the team and infrastructure. If I want strong portability across local, HPC, and cloud environments, Nextflow is often attractive because it integrates well with containers and supports flexible execution back ends. If the team wants a very readable Python-like syntax and the pipeline is relatively straightforward, Snakemake can be a great fit. WDL is also strong in environments that already use Cromwell and want explicit task definitions. My main criteria are: how easy it is for the team to maintain, how well it handles parallelization and retries, how cleanly it supports containers, and whether it fits the existing computing environment. I also consider observability, like logging and provenance. In practice, I’d rather choose the tool the team can operate confidently than the one that looks most impressive on paper. Long-term success usually depends more on adoption and maintainability than on syntax preference.
Question 5
Difficulty: easy
How would you ensure reproducibility when using a mix of open-source bioinformatics tools that update frequently?
Sample answer
Reproducibility starts with pinning everything that can change. I’d lock tool versions, reference genomes, annotation files, and container images so a run six months later can produce the same result. I prefer containers because they capture the runtime environment more completely than just listing package versions. I’d also track workflow code in version control and tag releases so each analysis can be traced to a specific commit. For external data sources, I’d store checksums and document exactly where the files came from. On top of that, I’d keep a run manifest with sample metadata, parameters, and timestamps. If the pipeline uses random seeds anywhere, I’d make those explicit too. I also think reproducibility is about operational habits, not just tooling, so I’d set up automated tests and compare outputs against known benchmarks whenever I update a tool. That way, if a newer version improves performance but changes results, the team can evaluate the impact intentionally instead of discovering it after the fact.
Question 6
Difficulty: easy
How do you handle large genomic datasets efficiently without sacrificing analysis quality?
Sample answer
I try to think about efficiency in terms of data movement, compute cost, and human time. For large genomic datasets, unnecessary file copying can become a major bottleneck, so I minimize intermediate files where possible and use streaming or compression appropriately. I also design workflows to parallelize naturally across samples or genomic intervals while avoiding over-fragmentation that creates management overhead. For storage, I’m careful about retaining only what’s needed for reproducibility and downstream use, rather than keeping every temporary artifact forever. I also pay attention to format choices, because converting between formats repeatedly can waste time and introduce errors. At the same time, I won’t optimize so aggressively that I lose quality control. I’d rather keep a few well-chosen checkpoints than save ten minutes and miss a bad batch. When performance matters, I profile the slowest steps, measure before changing anything, and validate that the optimized version gives the same scientific output. That balance is important in bioinformatics, where speed without correctness is not useful.
Question 7
Difficulty: medium
Tell me about a time you had to work with scientists or wet-lab researchers who were not familiar with bioinformatics constraints. How did you communicate with them?
Sample answer
I’ve found that the best way to work with non-bioinformaticians is to translate technical constraints into experimental consequences. Instead of saying a sample has low mapping quality, I’d explain that the data may not support confident conclusions for the region or assay they care about. I usually start by asking what decision they need to make from the analysis, because that helps me focus on what matters. In one project, the researchers wanted a fast turnaround, but the sample quality was inconsistent. Rather than simply saying the analysis was unreliable, I showed them which QC metrics were failing and how those metrics affected the confidence of the final result. That made the tradeoff concrete. I also try to provide a few options, such as rerunning a sample, adjusting thresholds, or narrowing the question. Clear visuals help a lot too. I’ve learned that good communication is not about simplifying the science too much; it’s about making the implications understandable so the team can make informed decisions together.
Question 8
Difficulty: hard
How would you validate a new bioinformatics pipeline before putting it into production?
Sample answer
I’d validate it in layers. First, I’d check that each component behaves as expected on a small, known dataset with ground truth or a trusted reference output. That tells me whether the basic logic is correct. Next, I’d run end-to-end tests on representative samples that capture the variety we expect in production, including edge cases like low coverage, contamination, or unusual insert sizes. I’d compare key outputs against a benchmark pipeline or published expectations, but I wouldn’t rely on exact file equality alone because some tools are nondeterministic or version-sensitive. I’d look at biologically meaningful metrics instead, such as sensitivity, precision, coverage, and QC failure rates. I’d also test operational aspects: restart behavior, logging, error messages, and how the pipeline performs under realistic load. Finally, I’d involve a domain expert to review the results and confirm they make sense biologically. A pipeline is production-ready only when it is accurate, explainable, and dependable under real conditions.
Question 9
Difficulty: hard
What would you do if a pipeline you built suddenly started producing different results after a dependency update?
Sample answer
My first move would be to stop the update from propagating further and compare the new results against the last known good run. I’d identify whether the change is coming from a tool version, a reference file, a parameter default, or a downstream dependency. Then I’d isolate the difference by rerunning the affected step with the old and new versions in the same environment if possible. If the output change is real, I’d assess whether it’s an improvement, a regression, or just a harmless formatting difference. In bioinformatics, small changes can have major biological consequences, so I’d review metrics, not just output files. If the update is beneficial, I’d document the impact, update tests, and communicate the change clearly to users. If it’s a regression, I’d roll back or pin the version until there’s a fix. I’d also use the incident to strengthen the release process, perhaps by adding comparison tests or a staging environment. The goal is not to avoid all change, but to make change controlled and evidence-based.
Question 10
Difficulty: easy
Why do you want to work as a Bioinformatics Engineer, and what makes you effective in this role?
Sample answer
I like this role because it sits right at the intersection of rigorous science and practical engineering. I’m motivated by the idea that well-built tools can turn complex biological data into results people can trust and use. What I enjoy most is taking something messy, like heterogeneous sequencing data, and building a workflow that makes it reliable, repeatable, and accessible to others. I think I’m effective in this role because I’m comfortable moving between details and big picture. I can dig into a weird alignment issue, but I also think about maintainability, testing, and how analysts will actually use the output. I’m also collaborative, which matters a lot in bioinformatics because the best solutions usually come from working closely with scientists, engineers, and stakeholders. I don’t assume that a pipeline is done when it runs once; I think it’s done when it consistently produces scientifically meaningful results and can be maintained by the team. That mindset has served me well in previous projects.
